Founding Date | 1987 |
Total Funding | $171.7 m |
Investors | New Enterprise Associates, Mayfield Fund, Venrock, Warburg Pincus, Alta Partners, Bridge Bank, Skyline Ventures, Bay City Capital, Vision Capital Advisors, Merlin Nexus, OpusPoint Partners, Caxton Advantage Life Sciences Fund, Abingworth, Nextech Invest, Credit Suisse First Boston, Rothschild & Cie, New Medical Technologies |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 5.0m | 3.8m | 8.0m | 5.7m | 3.1m | 2.5m | 669.0k | 237.0k | 2.1m | 120.0k |
R&D expense | 22.6m | 29.2m | 28.9m | 27.7m | 23.7m | 22.9m | 21.5m | 14.6m | 15.4m | 12.3m |
General and administrative expense | 8.3m | 9.2m | 10.8m | 23.1m | 18.7m | 16.1m | 13.5m | 11.3m | 9.9m | 10.2m |
Operating expense total | 30.9m | 38.4m | 39.7m | 50.8m | 42.4m | 39.0m | 35.1m | 25.9m | 25.4m | 22.4m |
EBIT | (25.9m) | (34.6m) | (31.8m) | (45.0m) | (39.3m) | (36.5m) | (34.4m) | (25.7m) | (23.3m) | (22.3m) |
EBIT margin, % | (517%) | (922%) | (399%) | (786%) | (1284%) | (1438%) | (5145%) | (10848%) | (1123%) | (18586%) |
Interest expense | 109.0k | 1.9m | ||||||||
Pre tax profit | (34.6m) | (43.0m) | (36.7m) | (38.0m) | (35.5m) | (26.6m) | (23.3m) | (21.6m) | ||
Income tax expense | ||||||||||
Net Income | (20.1m) | (44.0m) | (34.6m) | (43.0m) | (36.7m) | (38.0m) | (35.5m) | (26.6m) | (23.3m) | (21.6m) |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|
Net Income | (20.1m) | (44.0m) | (34.6m) | (43.0m) | (36.7m) | (38.0m) | (35.5m) | (26.6m) | (23.3m) | (21.6m) |
Depreciation and Amortization | 56.0k | 31.0k | 20.0k | 29.0k | 27.0k | 11.0k | 9.0k | 9.0k | (70.0k) | (41.0k) |
Accounts Payable | 242.0k | (580.0k) | 875.0k | 2.2m | (724.0k) | (582.0k) | (174.0k) | (304.0k) | (602.0k) | (312.0k) |
Cash From Operating Activities | (22.8m) | (10.6m) | (37.4m) | (43.2m) | (38.7m) | (37.0m) | (36.1m) | (24.4m) | (22.2m) | (21.4m) |
Purchases of PP&E | (15.0k) | (48.0k) | (26.0k) | |||||||
Cash From Investing Activities | 4.2m | (21.4m) | 32.2m | 3.3m | 1.2m | (15.0m) | 29.7m | 4.8m | (16.3m) | 16.4m |
Short-term Borrowings | (7.2m) | (9.4m) | (1.6m) | (8.0m) | (7.6m) | (7.5m) | (5.5m) | |||
Cash From Financing Activities | 13.7m | 37.6m | 5.4m | 46.9m | 42.2m | 33.1m | 25.3m | 6.3m | 43.0m | 7.2m |
Net Change in Cash | (4.9m) | 5.6m | 181.0k | 7.1m | 4.7m | (18.8m) | 18.9m | (13.3m) | 4.6m | 2.1m |
Interest Paid | 109.0k | 1.2m | 2.0m | 1.2m | 631.0k | 1.2m | 1.1m | 790.0k | 695.0k | 339.0k |
USD | Q2, 2011 |
---|---|
Financial Leverage | 1.3 x |